Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)

Titre officiel

A Pragmatic Randomised, Multicentre Trial Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)

Sommaire:

L’essai REaCT-RETT démontrera la non-infériorité de l’endocrinothérapie concomitante par rapport à l’endocrinothérapie séquentielle chez des patientes recevant une radiothérapie postopératoire pour un cancer du sein au stade précoce.

Description de l'essai

Primary Outcome:

  • Endocrine toxicity
Secondary Outcome:
  • Radiotherapy toxicity
  • Rates of starting endocrine therapy and compliance
  • Direct Estimation of Health Utility Values
  • Incremental cost-effectiveness ratios
  • Exploratory analyses on evaluating radiation therapy toxicity
Clinical equipoise exists around the optimal time to start adjuvant endocrine therapy in patients who will receive post-operative radiation therapy for breast cancer. Patients receive either concurrent or sequential endocrine and radiation therapy, where concurrent therapy consists of endocrine therapy started before, with or during radiation therapy, while sequential treatment is defined as endocrine therapy starting after the completion of radiation therapy. A recent survey of Canadian oncologists showed that the main reason for prescribing sequential endocrine therapy was a concern that concurrent endocrine therapy and radiation therapy would worsen the toxicity of endocrine treatment. This is despite the absence of any clinical trial evidence to support this. Indeed, a recent systematic review by our group was unable to confirm or refute whether increased toxicities, related to the timing of endocrine therapy and radiation therapy actually exist in clinical practice. The investigators are therefore proposing a pragmatic randomised trial to assess whether or not concurrent endocrine therapy and radiation therapy worsens endocrine treatment-related symptoms in an era of modern endocrine and radiation therapy.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer